A comparison between different postoperative treatment modalities of uterine carcinosarcoma

Menczer, Joseph; Levy, Tally; Piura, Benjamin; Chetrit, Angela; Altaras, Marco M.; Meirovitz, Mihai; Glezerman, Marek; Fishman, Ami

doi:10.1016/j.ygyno.2004.12.006

Cited by 66 publications

(36 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a phase II study, pelvic radiation "sandwiched" between chemotherapy was reported as efficacious treatment (Einstein et al, 2012). In a retrospective study of 49 patients with uterine MMMT, adjuvant sequential chemotherapy and radiotherapy significantly decreased mortality rate compared to adjuvant chemotherapy alone (Menczer et al, 2005). Our study suggested that adjuvant sequential chemotherapy and radiotherapy for uterine sarcomas improved RFS and had no effect on OS.…”

Section: 1935 Prognostic Factors and Treatment Outcomes In Patients mentioning

confidence: 61%

“…Addition of lympadenectomy to this procedure is indicated for MMMT group, because of high incidence of lymph node metastasis which was reported as 15-21% (Ali & Wells, 1993;Sartori et al, 1997;Menczer et al, 2005;Temkin et al, 2007;Gaducci et al, 2008). For localized leiomyosarcoma, the incidence of involvement of lymph node is rare, therefore lympadenectomy is not recommended (Gaducci et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey

Durnalı¹,

Tokluoğlu²,

Özdemir³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Median overall survival (OS) was 56 months (95% CI, 22.5-89.5 months), and OS after 1, 2, 5 years was 84.7%, 78%, 49.4% respectively. Multivariate analysis showed that age ≥60 years and high grade tumor were significantly associated with poor OS and RFS; patients administered adjuvant treatment with sequential chemotherapy and radiotherapy had longer RFS time. Among patients with leiomyosarcoma, in addition to age and grade, adjuvant treatment with sequential chemotherapy and radiotherapy after surgery had significant effects on OS. Conclusion: Uterine sarcomas have poor progrosis even at early stages. Prognostic factors affecting OS were found to be age and grade.

show abstract

Section: 1935 Prognostic Factors and Treatment Outcomes In Patients mentioning

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey

Durnalı¹,

Tokluoğlu²,

Özdemir³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…However, there is now considerable evidence that uterine CSs originate from a monoclonal cell. 3,4 In fact, the current accepted World Health Organization (WHO) classification for this group of female pelvic malignancies is no longer as uterine sarcomas but rather as mixed epithelial and stromal tumors. 5 The primary modality of therapy for uterine CS is surgery, consisting of the following: total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), retroperitoneal lymph node dissection (RPLND), and collection of peritoneal washings along with resection of any gross intra-abdominal disease.…”

Section: Introductionmentioning

confidence: 99%

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus☆

Wolfson

Brady

Rocereto

et al. 2007

Gynecologic Oncology

246

154

View full text Add to dashboard Cite

PURPOSE-After initial surgery, there has been no established consensus regarding adjunctive therapy for patients with uterine carcinosarcoma (CS). This study was designed to compare patient outcome following treatment with adjuvant whole abdominal irradiation (WAI) versus (vs) chemotherapy for patients with this rare group of female pelvic malignancies.PATIENTS AND METHODS-Eligible, consenting women with stage I-IV uterine CS, no more than 1 cm postsurgical residuum and/or no extra-abdominal spread had their treatments randomly assigned as either WAI or three cycles of cisplatin (C), ifosfamide (I), and mesna (M).RESULTS-232 patients were enrolled, of whom 206 (WAI=105; CIM=101) were deemed eligible. Patient demographics and characteristics were similar between arms. FIGO stage (both arms) was: I=64 (31%); II=26 (13%); III=92 (45%); IV=24 (12%). The estimated crude probability of recurring within 5 years was 58% (WAI) and 52% (CIM). Adjusting for stage and age, the recurrence rate was Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. CONCLUSION-We did not find a statistically significant advantage in recurrence rate or survival for adjuvant CIM over WAI in patients with uterine CS. However, the observed differences favor the use of combination chemotherapy in future trials. NIH Public Access

show abstract

“…It has been seen that patients having predominant epithelial element show a better response rate to chemotherapy (87.5%) than with patients with predominat sarcomatous component [13]. Studies have shown that patients undergoing chemo-radiotherapy have decreased mortality as compared to patients taking irradiation or chemotherapy alone [14]. But the role of neo adjuvant and adjuvant chemo-radiotherapy is debatable and its effect on survival is controversial.…”

Section: Discussionmentioning

confidence: 99%

Uterine Malignant Mixed Mullerian Tumour - Revisited In Newer Lights : A Case Report From A Tertiary Care Centre

Sarangi

Mahata

Mukherjee

et al. 2015

Int Jour of Biomed Res

View full text Add to dashboard Cite

Carcinosarcoma of the uterus, also known as malignant mixed mullerian tumour (MMMT) is a very rare and aggressive gynaecological neoplasm, having an overall poor prognosis. They can arise in any organ of the female genital tract but are most commonly found in uterus. They are histologically biphasic having malignant epithelial and mesenchymal components. We report a case of uterine MMMT, clinically presenting as uterine polyp, in a postmenopausal female.

show abstract

A comparison between different postoperative treatment modalities of uterine carcinosarcoma

Cited by 66 publications

References 36 publications

Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey

Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus☆

Uterine Malignant Mixed Mullerian Tumour - Revisited In Newer Lights : A Case Report From A Tertiary Care Centre

Contact Info

Product

Resources

About